<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772264</url>
  </required_header>
  <id_info>
    <org_study_id>B3291018</org_study_id>
    <nct_id>NCT01772264</nct_id>
  </id_info>
  <brief_title>Safety And Tolerability Study Of BID Titration Scheme With PF-05089771</brief_title>
  <official_title>An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-05089771 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most notable tolerability finding from these multiple dosing studies has been the
      occurrence of mild to moderate rash at doses of 450 mg BID and 600 mg BID. Based upon this
      finding, the current four week study is designed to examine whether a slow titration regimen
      up to a lower maintenance dose of 450 mg BID is able to reduce the incidence of rash.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>12h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>12h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration (Cmin)</measure>
    <time_frame>12h post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A - active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>titration from 150mg BID to 450mg BID</description>
    <arm_group_label>Arm A - active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Arm B - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects of non-child bearing potential between the ages of
             18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities
             identified by a detailed medical history, full physical examination, including blood
             pressure and pulse rate

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal (ie, recurrent
             nephrolitisis), endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,
             psychiatric, neurologic, or allergic disease (including drug allergies, but excluding
             untreated, asymptomatic, seasonal allergies at time of dosing).

          -  History of, or presence of allergic skin reactions or active skin disease (except for
             subjects with acne who may be included in the study) at the time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291018&amp;StudyName=Safety%20And%20Tolerability%20Study%20Of%20BID%20Titration%20Scheme%20With%20PF-05089771</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

